IMPROVING MEDICINES FOR CHILDREN IN CANADA FINDINGS OF THE EXPERT PANEL ON THERAPEUTIC PRODUCTS FOR INFANTS, CHILDREN AND YOUTH

Main Article Content

Gideon Koren

Keywords

children, Therapeutic Products for Infants

Abstract

With children being largely orphaned from the benefits of drugs, and being managed mostly by medications unapproved by Health Canada, a landmark document was published in September 2014 by the Council of Canadian Academies (CCA) to serve as a blueprint to change this grim reality. I t is now the task of governments, academia and the public at large to ensure that we follow this new road map and take care of our children as they deserve and expect us to do.

Abstract 110 | PDF Downloads 37

References

1. Qualifying for Pediatric Exclusivity Under Section 505A of the Federal Food, Drug, and Cosmetic Act: Frequently Asked Questions on Pediatric Exclusivity (505A), The Pediatric "Rule," and their Interaction. Accessed December 1, 2014. http://www.fda.gov/Drugs/DevelopmentAppr ovalProcess/DevelopmentResources/ucm0779 15.htm
2. Council of Canadian Academies - Improving Medicines for Children in Canada [Internet]. [cited on 2014 Oct 15]. Available from: http://www.scienceadvice.ca/en/assessments/completed/therapeutic - products.aspx
3. MICYRN: http://www.micyrn.ca/ Accessed December 1, 2014.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>